- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03765580
The Influence of Fish Consumption on Polyunsaturated Fatty Acid (PUFA) Status (iFish)
December 4, 2018 updated by: University of Ulster
The Influence of Fish Consumption on Polyunsaturated Fatty Acid (PUFA) Status (iFish Study)
Polyunsaturated fatty acids (PUFA) are important for health, for example for the immune system, heart health and the brain.
PUFA are found in fish, nuts and oils; including these foods in the diet provides the body with PUFA.
The body can also produce some PUFA in a series of steps.
It has been found that genetics influences the levels of PUFA produced in the body.
This study will investigate whether fish consumption influences PUFA status in women of childbearing age when accounting for FADS genotype by conducting a controlled human intervention study.
Participants will be asked to consume none, one or two portions of oily fish per week for 8 weeks and their response in PUFA status measured.
This study will also use collected blood, hair, urine and faecal samples collected from the intervention study to explore other biomarkers of fish consumption.
The aim of this study is to investigate whether fish consumption influences PUFA status in women of childbearing age when accounting for FADS genotype and to explore the potential of a novel biomarker, using hair MeHg:δ34S values, to accurately predict fish consumption.
The study will initially involve providing a buccal swab sample which will investigate genes which are related to fatty acids.
The participant will provide a buccal swab sample so that their genotype can be determined.
The researcher who will contact the participant once genotype has been determined to arrange a baseline appointment.
Participants will attend the Human Intervention Studies Unit at Ulster University, Coleraine once or twice weekly for a period of 8 weeks where they will receive lunch.
This lunch will contain either tuna, sardines, or no fish depending on the intervention group you will be allocated to.
Examples of lunch time meals they may receive include sandwiches, baked potato or salad which will include the type of fish they have been allocated to receive.
Those allocated to the no fish group will receive a fish free alternative lunch.
Participants will be asked to continue to follow their normal diet and lifestyle over the intervention period of 8 weeks.
All participants will attend a baseline and post intervention appointment where they will have weight, height and body composition measured.
Participants will also complete questionnaires to provide medical, lifestyle and dietary information.
All participants will be asked to provide a sample of blood, urine, hair and faeces to assess biomarkers of fish consumption at baseline and post intervention appointments.
Collected blood, urine, hair and faecal samples will be analysed for biomarkers of fish consumption.
Participants will also be asked to return to the Human Intervention Studies Unit (HISU) 8 weeks after the intervention study has been completed (week 16) to provide a third hair sample and complete a Fish Feedback Questionnaire.
In the 8 wks following conclusion of the study they will be free to return to their normal diet.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Co.Londonderry
-
Coleraine, Co.Londonderry, United Kingdom, BT52 1SA
- Human Intervention Studies Unit, Ulster University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 41 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy females - premenopausal, child-bearing age, not planning to become pregnant
- Age 18-45years old
- Low consumers of fish (<2 portions/ week) or those willing to reduce their fish consumption one month prior to commencing the study to the equivalent of 2 portions per month or less
- Willing to eat 1 or 2 portions (140 grams or 280 grams) of either tuna or sardines per week for a period of 8 weeks
- Not consuming fish oil supplements
- Not consuming protein supplements
- Not allergic to seafood
Exclusion Criteria:
- Regularly eat fish or not willing to do washout period where they reduce fish consumption
- Are allergic to seafood
- Are taking fish oil supplements or are taking protein supplements
- Are pregnant or menopausal
- Have very short hair (a small section of hair, approximately 200 strands, will be taken at the nap of the neck for analysis purposes)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control group
No fish
|
Lunch containing no fish
|
|
Experimental: 1 portion of fish per week
140g fish/week
|
Lunch containing fish
|
|
Experimental: 2 portions of fish per week
280g fish/week
|
Lunch containing fish
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Polyunsaturated fatty acid (PUFA) status
Time Frame: Change at 8 weeks from baseline
|
Serum Polyunsaturated fatty acid (PUFA) status
|
Change at 8 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hair mercury
Time Frame: Change at 8 & 16 weeks from baseline
|
Hair mercury status
|
Change at 8 & 16 weeks from baseline
|
|
Lipid profile
Time Frame: Change at 8 weeks from baseline
|
Serum lipid profile
|
Change at 8 weeks from baseline
|
|
Iodine
Time Frame: Change at 8 weeks from baseline
|
Urine iodine
|
Change at 8 weeks from baseline
|
|
Inflammatory status
Time Frame: Change at 8 weeks from baseline
|
Cytokine concentration (Interleukin (IL)-5, IL-1β, IL-2, IL-4, IL-6, IL-10, MCP-1, TARC, sFlt-1, VEgF-D, CRP, TNF-α, IFN-γ)
|
Change at 8 weeks from baseline
|
|
Oxidative stress
Time Frame: Change at 8 weeks from baseline
|
Change in glutathione peroxidase and 8-isoprostanes
|
Change at 8 weeks from baseline
|
|
Microbiota
Time Frame: Change at 8 weeks from baseline
|
Faecal microbiota profile
|
Change at 8 weeks from baseline
|
|
Thyroid hormones
Time Frame: Change at 8 weeks from baseline
|
Serum T3, T4 and thyroid-stimulating hormone (TSH).
Dried blood spot for thyroglobulin, T4 and TSH
|
Change at 8 weeks from baseline
|
|
Stable isotopes
Time Frame: Change at 8 & 16 weeks from baseline
|
Hair methyl-mercury and sulphur-34
|
Change at 8 & 16 weeks from baseline
|
|
Methyl-mercury (MeHg)
Time Frame: Change at 8 weeks from baseline
|
Whole blood and urine MeHg
|
Change at 8 weeks from baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2016
Primary Completion (Actual)
May 31, 2017
Study Completion (Actual)
May 31, 2017
Study Registration Dates
First Submitted
December 4, 2018
First Submitted That Met QC Criteria
December 4, 2018
First Posted (Actual)
December 5, 2018
Study Record Updates
Last Update Posted (Actual)
December 5, 2018
Last Update Submitted That Met QC Criteria
December 4, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- REC/16/0077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polyunsaturated Fatty Acid (PUFA) Status
-
Research Institute of Child Nutrition, DortmundCompletedIron Status | Fatty Acid StatusGermany
-
Research Institute of Child Nutrition, DortmundUniversity of Potsdam; Dr. von Hauner Children's Hospital, Germany; Pediatric...Completed
-
Zhejiang UniversityNational Institute of Health and NutritionCompletedMortality | Polyunsaturated Fatty Acids
-
Josip Juraj Strossmayer University of OsijekUnknownOmega-3 Polyunsaturated Fatty AcidsCroatia
-
Riga Stradins UniversityCompletedSupplementation | Lipid Metabolism | Omega-3 Polyunsaturated Fatty AcidsLatvia
-
Josip Juraj Strossmayer University of OsijekUnknownVitamin E | Selenium | Lutein | n-3 Polyunsaturated Fatty AcidsCroatia
-
Josip Juraj Strossmayer University of OsijekRecruitingn-3 Polyunsaturated Fatty AcidsCroatia
-
Mario Negri Institute for Pharmacological ResearchRecruitingInflammation | Lipids | Cardiovascualr Disease | n-3 Polyunsatured Fatty Acids (n-3 PUFA)Italy
-
NorthShore University HealthSystemAnn & Robert H Lurie Children's Hospital of Chicago; Northwestern University... and other collaboratorsCompletedPremature, Extremely Low Birth Weight Infants | Polyunsaturated Fatty Acid LevelsUnited States
-
Allama Iqbal Open University IslamabadKing Edward Medical UniversityCompletedRole of Omega-3 Polyunsaturated Fatty Acid in the Management of Major Depressive Disorder: A Randomized Controlled TrialPakistan
Clinical Trials on Control
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationCritical Illness | Respiratory Failure | Mechanical VentilationUnited States
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
The George InstituteChanghai Hospital; University of CalgaryRecruitingIschemic Stroke, AcuteCanada, Australia
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Takeshi MorimotoUniversity of the RyukyusCompletedCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Yonsei UniversityRecruitingHypertension | Chronic Kidney Diseases | DyslipidemiasKorea, Republic of